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Inter-Regulation of Th17 Cytokines and the IL-36
Cytokines In Vitro and In Vivo: Implications
in Psoriasis Pathogenesis
Yijun Carrier1,3, Hak-Ling Ma1,3, Hilda E. Ramon1, Lee Napierata1, Clayton Small2, Margot O’Toole2,
Deborah A. Young1, Lynette A. Fouser1, Cheryl Nickerson-Nutter1, Mary Collins1,
Kyri Dunussi-Joannopoulos1 and Quintus G. Medley1
Accumulating evidence indicates that IL-1 family members and Th17 cytokines have a pathogenic role in
psoriasis. We investigated the regulatory interactions of the IL-1-like IL-36 cytokine family and the Th17
cytokines in the context of skin inflammation. We observed increased gene expression of all three IL-36
cytokines in a Th17-dominant psoriasis-like animal model. The induction was downregulated by neutralizing
IL-22. Expression of the IL-36s was also induced in cultured primary human keratinocytes (KC) by IL-17A and
tumor necrosis factor (TNF)-a, and IL-22 synergized with IL-17A and TNF-a. Furthermore, the IL-36s directly
induced their own expression and the production of proinflammatory mediators (TNF-a, IL-6, IL-8) in KC. These
functions were markedly enhanced with the addition of IL-17A or TNF-a to the cultures. Similarly, IL-36a and
IL-36b augmented IL-17A-mediated induction of antibacterial peptides. Finally, we show that the increased gene
expression of IL-36 correlated with Th17 cytokines in the lesions of psoriatic patients. Our results indicate that
the IL-36 cytokines are not only regulated by Th17 cytokines, but that they themselves can regulate the
expression and enhance the function of Th17 cytokines. We propose that a feedback loop between the IL-36
and Th17 cytokines is involved in driving cytokine expression in psoriatic tissues.
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INTRODUCTION
IL-36 is a newly named cytokine family that comprises three
members: IL-36a, IL-36b, and IL-36g, previously designated
IL-1F6, IL-1F8, and IL-1F9, respectively (Dinarello et al.,
2010), as a result of their homology to IL-1 (Kumar et al.,
2000; Smith et al., 2000). Similar to the classical IL-1
cytokines, IL-36 cytokines are also involved in the initiation
or regulation of immune responses (Sims and Smith, 2010).
All IL-36 cytokines bind IL-1 receptor (IL-1R)-related protein
2, which in turn recruits the signal component IL-1RAcp, the
accessory protein (Acp) that is also shared by IL-1a and IL-1b,
and activates a signaling pathway similar to IL-1a and IL-1b
(Sims, 2002; Towne et al., 2004). Different from IL-1a and
IL-1b, IL-36s are expressed in a restricted manner, primarily
in the skin and other epithelial tissues, whereas the receptors
are more widely expressed (Kumar et al., 2000; Smith et al.,
2000; Sims et al., 2006). Transgenic overexpression of IL-36a
in basal KC in mice results in cutaneous alterations in both
the epidermis and dermis, which is independent of T-cell
involvement (Blumberg et al., 2007). In addition, increased
IL-36a levels have been observed in psoriasis vulgaris
biopsies, indicating that the IL-36 cytokines may have a
proinflammatory role in this disease (Blumberg et al., 2007).
Psoriasis vulgaris is a common chronic inflammatory skin
disorder mediated by T-cell interactions with KC and other
types of skin-infiltrating immune cells. Recent discoveries
have highlighted the involvement of Th17 T-helper cells and
the cytokines they produce in psoriasis (Wilson et al., 2007;
Pene et al., 2008). However, the mechanisms by which Th17
cytokines contribute to the pathogenesis of psoriasis still
remain unclear. Here, we explored the inter-regulation of
the IL-36 cytokines and the Th17 cytokines, and elucidated
the contributions of this family of innate immune cytokines
in the cytokine network of human psoriasis.
RESULTS
Increased gene and protein expression of IL-36 cytokines in
psoriasis-like mouse skin lesions
We have previously described a psoriasis-like mouse model,
which involves the adoptive transfer of naive CD4þ
CD45RBhiCD25 cells into CB17 scid/scid mice (Ma et al.,
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2008). The transferred T cells elicit a Th17-dominant immune
response and induce scaly and raised skin plaques with
certain microscopic characteristics resembling human
psoriasis. In the ear samples that contain these psoriasis-
like plaques, we detected significantly elevated gene expres-
sion of all three IL-36 cytokines (mRNA of Il1f6, Il1f8, and
Il1f9) when compared with control mice that did not receive
T-cell transfer, hence without skin lesions (Figure 1a). The
expression of their unique receptor IL-1R-related protein 2
(gene symbol: Il1rl2) was increased slightly, but did not reach
the level of statistical significance. Markedly elevated IL-36a
protein was also detected in the ear biopsies with psoriatic-
like plaques (Figure 1b), indicating that the protein level was
consistent with the observed increased gene expression.
IL-22 regulates the expression of IL-36 cytokines in normal and
psoriasis-like mouse skin
We have previously demonstrated that Th17 cells are major
effectors driving disease progression in this T-cell-adoptive
transfer psoriasis-like model, and that IL-22 neutralization
alone is sufficient to prevent disease progression (Ma et al.,
2008). Using the same neutralizing regimen in this model, we
found that the diminished symptoms in the recipients of anti-
IL-22 antibody correlated with reductions in Il1f6 (B9-fold),
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Figure 1. Regulation of IL-36 cytokines by IL-22 in mouse psoriasis-like skin. Tissue lysates from scid mice that received either naive T cells or saline (control)
(a) and that co-received antibodies (isotype control or anti-IL-22) and naive T cells (c) were analyzed for the mRNA expression of mouse Il1f6, Il1f8, Il1f9,
and Il1rl2 by quantitative PCR. In addition, ear tissues with or without psoriatic-like plaques were analyzed for the expression of IL-36a protein by western
blot (b). (d) Ear tissues from naive BALB mice that received saline (control) or rmIL-22 were also subjected to the same gene expression analysis. One of two
(a, total n¼8, *Po0.005), one of three (c, n¼ 5 per group, *Po0.01), and one of two (d, n¼ 4 per group, **Po0.1) independent experiments. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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Il1f8 (B2.3-fold), and Il1f9 (B2.2-fold), but not Il1rl2
transcripts (Figure 1c). In contrast, repeated injection of
recombinant IL-22 protein in the normal skin of wild-type
BALB/c mice induced gene expression of all IL-36s
(Figure 1d). These data suggest that the Th17 cytokine IL-22
can regulate gene expression of IL-36s, but not the receptor,
at the site of inflammation.
IL-22, IL-17A, and tumor necrosis factor-a induce the ex vivo
production of all three IL-36 by human KC, whereas IFN-c
selectively induces IL-36b
To further delineate the effects of IL-22 on the expression of
IL-36s, we used a primary human epithelial KC culture
system and studied the effects of IL-22 when added to this
culture system. Despite a vast difference in the relative
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Figure 2. Induction of IL-36 gene expression in human primary keratinocytes (KC) in vitro. KC were incubated with (a) 0.32, 1.6, 8, 40, or 200 ngml1 of IL-22,
(b, c) 200 ngml1 of IL-22 in combination with IL-17A, (d) IL-22 with tumor necrosis factor (TNF)-a, (e) IL-12 and IFN-g, (f) Th1 or Th17 cytokines alone or in
combination, as indicated, and (g) 1 mgml1 of IL-36 in the presence of IL-17A or TNF-a, all for 24 hours. Relative expression levels of indicated genes are
reported as mean±SD of triplicates of a representative donor. (c) IL-36g and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) proteins detected by
western blot analysis. The protein level of IL-36g wasB10 ng in 15mg of cell extract as judged using recombinant IL-36g as standards. Shown is one of four (a),
six (b), two (c), six (d), three (e, f), and two (g) experiments with a total of eight donors.
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transcript quantity of each member, a dose-dependent
increase in all three, IL1F6, IL1F8, and IL1F9, transcripts
was observed in KC from all donors tested (Figure 2a).
We have previously demonstrated that IL-22 and IL-17A
are coexpressed by Th17 cells, and that these two cytokines
have a synergistic effect in enhancing the production of
innate inflammatory ‘‘danger signals’’, such as b-defensin 2
and S100 proteins, by human KC (Liang et al., 2006). Here
we examined the regulation of IL-36s by IL-22, IL-17A, and
IL-17F, separately or in combination, in primary human KC
cultures. In contrast to the modest effects of IL-22, transcripts
of all IL-36s were profoundly induced in response to IL-17A,
with IL1F6 displaying the strongest increase (Figure 2b).
Addition of IL-22 further enhanced the induction of IL1F6,
and to a lesser extent, the induction of IL1F8 and IL1F9 by
IL-17A, indicating that IL-22 and IL-17A also have synergistic
or additive effects in the regulation of IL-36 cytokines. The
amount of IL-36g protein was increased B7-fold in KC that
were cocultured with IL-22 and IL-17A (Figure 2c), confirm-
ing the correlation between gene and protein expression.
Protein induction of IL-36g was B100-fold greater than
IL-36a, and protein level of IL-36b was below detection limits
(data not shown). IL-17F alone or in combination with IL-22
had no effect on the gene expression of IL-36s and their
receptor (data not shown).
Tumor necrosis factor (TNF)-a is another important
proinflammatory cytokine that is produced by Th17 cells.
Clinical studies have demonstrated that blocking the TNF
pathway is an effective treatment in psoriasis patients
(Gottlieb et al., 2005). TNF-a stimulation of the KC resulted
in a 10- to 20-fold increase in all three IL-36 mRNA levels
compared with cells cultured with media alone (Figure 2d).
TNF-a-mediated IL-36 induction could be further boosted
with the addition of IL-22 to the culture. Although IL-17A and
TNF-a induced all three IL-36 in the KC, IL-17A most strongly
induced the expression of IL-36a, and TNF-a strongly
induced IL-36b.
The induction and progression of tissue damage in
psoriasis has been traditionally linked to Th1 T cells and
their signature cytokines IFN-g and IL-12 (Lowes et al., 2007).
Incubation with IFN-g alone induced about a 10-fold
increase of IL1F8 transcript while having minimal effect on
IL1F6 and IL1F9 mRNA (Figure 2e). IL-12 had no effect either
alone or in combination with IFN-g. These data demonstrate
that in our in vitro cultures, the expression of IL-36 in KC is
predominantly regulated by Th17 cytokines with some
contributions by Th1 cytokines.
We also examined the regulation of classic IL-1a and IL-1b
by Th1, Th17, and IL-36 cytokines in KC cultures. A slight
increase in the gene expression of IL1b was induced by
IL-17A (o2-fold, Figure 2f) and TNF-a (3-fold, Figure 2g)
in KC. However, IL-22, IFN-g, IL-12, and all three IL-36
showed minimal effects, either alone or in combination. The
lack of regulation of IL-1a/b by Th17 cytokines in our KC
cultures suggests that the regulation of IL-36s by Th17
cytokines is relatively specific, and there is distinct spatial
and temporal expression of the two branches of the IL-1
family.
IL-36 cytokines synergize with IL-17A and TNF-a to increase
their own expression
To elucidate the functions of the IL-36 family of cytokines in
local tissues, we first examined the ability of the IL-36s to
regulate their own expression, as related IL-1 cytokines are
able to do so. Primary KC were incubated with all three
IL-36s in a range of 0–10 mgml1 concentrations. As shown in
Figure 3a, both IL-36a and IL-36b induced the gene
expression of themselves and other family members in a
dose-dependent manner. IL-36a peaked around 3 mgml1
and IL-36b may not reach plateaus even at a concentration of
10 mgml1. This ‘‘self-induction’’ was significantly enhanced
with the addition of IL-17A (at constant concentration of
20 ngml1) in the cultures. All three IL-36 had synergistic
effects with IL-17A and the ‘‘self-induction’’ all peaked at
around a concentration of 1–3 mgml1. In fact, IL-36g, which
hardly induced the gene expression of itself and other
members, was able to stimulate the expression of all three
members in the presence of IL-17A in KC cultures. Synergistic
effects with TNF-a in self-induction were also observed when
IL-36s were used at concentrations of 1 mgml1 (Figure 3b)
and also in cross-induction of IL1F6 and IL1F9 by IL-36b
(Figure 3c). These data suggest that all three members of the
IL-36 family are capable of self-regulation in KC in vitro
cultures, with IL-36b having the strongest effects and IL-36g
the weakest. IL-17A and TNF-a not only induce IL-36
cytokines but also enhance their function in a selective
manner.
IL-36a and IL-36b induce proinflammatory mediators in human
KC in vitro
Next, we tested IL-36 for the ability of inducing proinflam-
matory cytokines in KC. We found that IL-36a and IL-36b, but
not IL-36g, directly induced TNF-a mRNA and protein
synthesis in KC (Figure 4a). IL-17A had little effect by itself,
but strongly enhanced IL-36a- and IL-36b-mediated induc-
tions of TNF-a. Interestingly, although TNF-a induced its own
expression, addition of IL-36a or IL-36b further strengthened
TNFa gene expression, indicating that IL-36a and IL-36b
could regulate TNF-a directly in KC. In addition, we observed
direct regulation of IL-8 and IL-6 by IL-36a and IL-36b, which
synergized with IL-17A and TNF-a (Figure 4b and c). In
testing the regulation of b-defensin (gene symbol DEF4) and
s100A7, two proteins previously shown to be elevated in
psoriatic lesions, all three IL-36 showed minimal direct
effects. However, when paired with IL-17A, IL-36a and
IL-36b further increased IL-17A-induced DEF4 mRNA by
2- and 6-fold, respectively (Figure 4d). Interestingly, similar
synergistic effects were observed between IL-17A and IL-36b
and IL-36g in S100a7 induction (Figure 4e). In addition, we
studied the effects of IL-36s on KC proliferation by examining
the gene expressions of keratin 16 and 17 (gene symbol:
KRT16 and KRT17), which are expressed at elevated levels by
KC in psoriasis (Leigh et al., 1995). After incubation of KC
with IL-36, either alone or in combination with IL-17A or
TNF-a, levels of KRT16 and KRT17 expression were
fluctuated within 1.0- to 1.5-fold for the 6–72 hour culture
period that was tested (Figure 4f and g, shown at 24 hours),
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indicating that IL-36s do not regulate K16 and K17 directly.
Together, these data suggest that IL-17A and TNF-a-induced
IL-36 in KC may enhance the pathogenic function of
IL-17A and TNF-a locally, thus contributing to the establish-
ment and perpetuation of a proinflammatory environment in
tissues.
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Figure 3. Self- or cross-regulation of gene expression of IL-36 cytokines in keratinocytes (KC) in vitro. Gene expression of human IL1F6, IL1F8, and IL1F9 in
KC after 24 hours of incubation with 0, 0.3, 1.1, 3.3, and 10mgml1 of IL-36a, IL-36b, and IL-36g in the absence or presence of 20 ngml1 of IL-17A (a),
or after incubation with 1 mgml1 of IL-36 alone or in combination with 20 ngml1 of tumor necrosis factor (TNF)-a (b, c). Data are reported as mean±SD
of triplicates of one representative donor out of five donors.
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Increased expression of IL-36 cytokines correlates with
expression of IL-17A, IL-22, TNF-a, and IFN-c in human
psoriasis skin lesions
Gene expression of a panel of proinflammatory cytokines was
examined in paired non-lesional and lesional skin samples
obtained from psoriatic patients. All patients had increased
expressions of IL1F6 (B20-fold), IL1F8 (B100-fold), and
IL1F9 (B4-fold) in the psoriatic lesions, either as a group or as
individual patients (Figure 5a). This increase strongly
correlated with the expression of Th17 cell-secreted cyto-
kines IL-22, IL-17A, and TNF-a, but not IL-17F (Figure 5b and
Table 1). In addition, elevated IFN-g expression was also
detected in the lesions and correlated well with the
expression of IL-36s, indicating a possible interplay between
Th1 and Th17 cytokines in psoriatic skin lesions. This is in
agreement with a very recent report showing that IFN-g
synergizes with IL-17 in the production of antimicrobial and
chemotactic proteins by psoriatic KC, suggesting that Th1 and
Th17 cytokines may all contribute to human psoriasis
(Kryczek et al., 2008).
DISCUSSION
This study characterizes the interplay between the systemic
proinflammatory cytokines IL-17A, IL-22, and TNF-a, which
are predominantly produced by immune cells, and the IL-36
cytokines, which are expressed in a restrictive manner,
primarily in the skin and epithelium. We demonstrate that the
IL-36s are not only regulated by Th17 cytokines, but that they
themselves can regulate the expression and enhance the
function of Th17 cytokines. We propose that the collabora-
tion between IL-36 and Th17 cytokines augments the
downstream function of both IL-36 and Th17 cytokines.
The relationship between the IL-36 and Th17 cytokines is
illustrated in our study first by the effect of IL-22 on their
in vivo expression in a Th17-dominant psoriatic-like mouse
model (Ma et al., 2008). Blockade of IL-22 signaling
downregulated the gene expression of all IL-36 cytokines
and skin inflammation in the psoriatic ear tissues, whereas
injection of recombinant IL-22 protein into the ears of naive
mice had opposite results (Figure 1; Ma et al., 2008). Using
an in vitro primary human KC culture system, we further
a
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Figure 5. Correlation between IL-36 and Th17 cytokine gene expression in the human psoriasis skin lesions. (a) Transcript levels of human IL1F6, IL1F8, IL1F9,
and IL1RL2 in non-lesional (non-L) or lesional skin biopsy pairs from human psoriasis patients (n¼11); *Po 0.02. (b) Comparison of human IL1F6, IL1F8,
and IL1F9 with IL22 and IL17a transcripts (units on x and y axis are in relative units normalized to transcripts of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)) in the lesional skin biopsies. Statistical correlations were determined according to Pearson’s value correlation test, and
differences between pairs of cytokines were determined by two-tailed Student’s t-test.
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demonstrated that IL-36 can be induced by Th17 cytokines.
IL-17A and TNF-a are strong inducers of IL-36s, whereas
IL-22, a weaker one by itself, has synergistic/additive effects
with IL-17A or TNF-a. This is in agreement with our previous
report that IL-22 has a synergistic/additive effect on the
induction of antimicrobial peptides by IL-17A or IL-17F
(Liang et al., 2006). Interestingly, we found that IL-36
cytokines also have a synergistic/additive effect on the
induction of antimicrobial peptides by IL-17A or TNF-a,
indicating that Th17 cytokines and IL-36 can reinforce similar
responses in KC. Levels of IL-20, a cytokine closely related to
IL-22, are elevated in psoriatic lesions and contribute to KC
differentiation (Wolk et al., 2009). It is possible that, similar to
IL-22, IL-20 may have a role in IL-36 expression in KC.
Although psoriasis is one of the most common T-cell-
mediated autoimmune diseases in humans, a role for the
innate immune system in triggering the T-cell cascade has
been proposed (Boyman et al., 2004; Nestle et al., 2005).
TNF-a is an important proinflammatory cytokine that initiates
and maintains inflammatory responses in the skin (Aggarwal,
2003), and clinical studies have demonstrated that blocking
the TNF pathway is an effective treatment in psoriasis patients
(Gottlieb et al., 2005). Here we show that the production of
TNF-a can be induced by either IL-36a or IL-36b in primary
human KC. The presence of IL-17A and TNF-a in the cytokine
milieu further augments the function of IL-36, driving the
production level of TNF-a even higher. In turn, TNF-a is a
potent inducer of all three IL-36s in KC. This amplification
loop involves cytokines produced by and functioning on KC
and can occur in the absence of T cells. In addition to the
induction of TNF-a, IL-36 induces proinflammatory media-
tors that are regulated by NF-kB (Towne et al., 2004),
including IL-6, IL-8, and the antimicrobial peptides. Our
findings are consistent with a recent report that IL-36
cytokines contribute to the pathogenesis of psoriasis by
inducing proinflammatory cytokines and a range of anti-
microbial peptides and matrix mettalloproteinases from
reconstituted human epidermis (Johnston et al., 2011). It is
possible that in cooperation with TNF-a, the innate immune
IL-36 cytokines are capable of initiating skin inflammation in
psoriasis in the absence of adaptive immunity. This may
partially explain the observation that transgenic overexpres-
sion of IL-36a protein in basal level KC can induce psoriasis-
like inflammation in lymphocyte-deficient Rag2 knockout
mice (Blumberg et al., 2007).
The regulation of IL-36 by Th17 cytokines we observed in
in vitro KC cultures and in the psoriasis-like mouse model is
consistent with gene expression levels seen in non-lesional
and lesional biopsy samples from psoriasis patients. Increased
expression of IL-36 is correlated with increased expression of
cytokines that are known to be involved in the pathogenesis
of psoriasis (IL-17A, IL-22, TNF-a, IL-23, and IFN-g, but not
IL-12 and IL-17F). We did not directly measure the relation-
ship between IL-36 and IL-23 in our in vitro assays, as IL-23 is
not made by nor does it directly affect KC. However, recent
genome-wide association studies have implicated IL23R
genetic variants as conferring risk to psoriasis, suggesting an
important role of the IL-23 pathway in the disease pathogen-
esis (Nair et al., 2009). We speculate that the correlation
between IL-23 and IL-36 is a result of the role of IL-23 in
generation of Th17 cells. This is consistent with the
observation that IL-36s induce IL-6 and TNF-a in KC that
Table 1. Correlation of cytokine expression profiles in
human psoriatic lesions
Gene symbol IL1F6 IL1F8 IL1F9 IL1RL2
IL12P35
r 0.324 0.324 0.524 0.154
P 0.331 0.332 0.098 0.651
R2 0.105 0.105 0.274 0.024
IL17a
r 0.848 0.795 0.705 0.037
P 0.001 0.004 0.015 0.913
R2 0.719 0.632 0.497 0.001
IL17f
r 0.491 0.562 0.237 0.351
P 0.125 0.072 0.482 0.290
R2 0.241 0.316 0.056 0.123
IL22
r 0.894 0.873 0.629 0.103
P 0.000 0.001 0.038 0.764
R2 0.799 0.761 0.395 0.011
IL23
r 0.588 0.600 0.790 0.000
P 0.057 0.051 0.004 1.000
R2 0.346 0.360 0.624 0.000
IFNg
r 0.863 0.810 0.862 0.171
P 0.001 0.003 0.001 0.615
R2 0.745 0.656 0.742 0.029
TNFa
r 0.618 0.677 0.676 0.162
P 0.043 0.022 0.023 0.635
R2 0.382 0.459 0.457 0.026
Comparison of human IL1F6, IL1F8, IL1F9, and receptor IL1RL2 gene
transcripts with those of the other cytokines in the lesional skin biopsies.
Statistical correlations were determined according to Pearson value
correlation test. The correlation coefficient, r, quantifies the direction and
magnitude of correlation. The quantity of the coefficient of determination,
R2, is the fraction of the variance that is ‘‘shared’’ between two variables.
P-values were determined by two-tail Student’s t-test.
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directly contribute to Th17 differentiation and maintenance.
However, this does not exclude a more direct effect of
IL-36 on Th17 generation, in a manner similar to that of
IL-1b, which is important for the differentiation and growth
of Th17 cells in humans (Acosta-Rodriguez et al., 2007).
Whether or not the IL-36 family members have similar
function as IL-1b in this context awaits future investigation.
The involvement of IL-36 in the adaptive immunity and this
mutual induction between IL-36 and Th17 cytokines have
also been demonstrated in a recent study using a psoriatic-
like mouse model induced by application of an irritant on the
skin of mice overexpressing IL-36a transgene (Blumberg
et al., 2010).
Both Th1 and Th17 cells have been verified as major
T-cell components of psoriasis (Lowes et al., 2008). It is still
not clear which cell type has a predominant role, although a
greater number of Th17 and Th22 cells are identified in the
circulations of psoriasis patients than Th1 cells (Kagami et al.,
2009). In this study, we show regulation of IL-36 by both
Th17 and Th1 cytokines. Although only the transcription of
IL-36b is stimulated by IFN-g in KC cultures, the gene
expressions of all three IL-36 are correlated with that of IFN-g
in the psoriatic plaques from patients. Interestingly, IL-36b is
a robust inducer of IL-36 family members in KC cultures,
indicating that increasing IL-36b expression could result in
increased expression of other members. Therefore, it is
possible that IL-36 cytokines are involved in mediating
effects from both Th1 and Th17 cytokines in psoriasis. It is
puzzling that although all members of IL-36 family bind to
their common receptor IL-1R-related protein 2, they clearly
convey different signals and thus may have different
activities. The differential effects of IL-36 cytokines may be
explained by the role of the N-terminal region of the proteins
on activity as it has been suggested that N-terminal cleavage
increases the activity of the IL-36 cytokines (Blumberg et al.,
2010), although the mechanism of such cleavage in vivo is
unclear. However, it is also possible that the functional
differences of IL-36 members may reflect intrinsic diversity of
these molecules and possible non-redundant roles played by
each member at the site of inflammation.
In summary, we have shown here the connection between
the Th17 cytokine network and the local expression of IL-36
in primary human KC, in a psoriatic-like mouse model and in
the lesions of psoriasis patients. Our data suggest that IL-36s
are not only effector cytokines downstream of their induction
by Th17 cytokines in the skin, but also inducers of many
proinflammatory mediators (cytokine, chemokine, and anti-
microbial peptide) that regulate the cellular and soluble
components of the local inflammatory milieu. The cross talk
between the Th17 cytokines and IL-36 family suggests that
levels of both cytokine classes can be amplified in a disease
setting with a resultant amplification in their activity,
and could perhaps have a role in the chronic autoimmune
inflammation observed during psoriasis. These findings
further characterize an innate immune pathway and its role
as a trigger of a common human autoimmune disease, and
suggest that IL-36 cytokines and their receptor represent
potential early targets for the treatment of psoriasis.
MATERIALS AND METHODS
Mice
Female BALB/cBy (donor) and C.B-17/prkdc scid/scid (recipient)
mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
All mice were housed in a specific pathogen-free environment at a
Pfizer animal facility and were used between 6 and 8 weeks of age.
All protocols were approved by the Pfizer Animal Care and Use
Committee.
Human sample
Human skin samples were obtained as described before (Bhawan
et al., 2004). An institutional approval was obtained for the biopsies
from each participating site with adherence to the Declaration of
Helsinki Principles. Patients provided written, informed consent.
Reagents
Anti-IL-22 neutralizing and isotype control antibodies, recombinant
mouse and human IL-22, and human IL-17A and IL-17F were
generated internally. Recombinant human IL-36a, IL-36b, IL-36g,
TNF-a, IFN-g and IL-12, and anti-mouse IL-36a and anti-human
IL-36g antibodies were purchased from R&D Systems (Minneapolis,
MN). All proteins are with endotoxin level o1.0 EUmg1 of
cytokine. We carefully tested and eliminated the effect of lipopoly-
saccharide (LPS) in our culture systems with exogenous LPS and LPS
antagonist polymyxin B.
Treatment of mice
Induction of psoriasis-like lesions in mice, treatment with anti-IL-22
antibody and intradermal injection of recombinant IL-22 were
described previously (Ma et al., 2008). Briefly, psoriatic-like
skin lesions were induced in C.B-17/Prkdc scid/scid mice after
adoptive transfer of naive CD4þCD45RBhiCD25 T cells isolated
from BALB/cBy mice. Tissues were harvested on day 70 for analysis.
Alternatively, mice that received naive T cells were also treated
with anti-IL-22 or the isotype control antibodies twice a week for
70 days. To evaluate the effects of IL-22 in normal mouse tissue,
naive BALB/cBy mice were injected intradermally every other
day for 2 weeks with saline (left ear) or rmIL-22 (right ear). Ears
were harvested and subjected to analysis of gene or protein
expression.
Keratinocyte cultures
Primary human epithelial KC (ScienCell, Carlsbad, CA) were
cultured in KC-conditioned medium on poly-D-lysine-coated plates
(BD Biosciences, Bedford, MA). Cells were passed at 80%
confluency and all experiments were conducted between passages
1 and 4. In all, 30,000 cells per well (24-well plate) were seeded
and allowed to adhere for 48 hours before cultured with cytokines.
IL-22 and IL-12 were used at 200 ngml1, IL-17A, TNF-a, IFN-g at
20 ngml1, and IL-36s at 1mgml1, unless indicated in the graph.
Quantitation of cytokine transcripts
RNA was isolated using the QIAGEN RNeasy kit (Qiagen, Valencia,
CA) and subjected to quantitative reverse transcription-PCR using
prequalified primers and probes from Applied Biosystems (Carlsbad,
CA). The DdCt method was used to normalize transcripts to GAPDH,
and reported as either unit relative to GAPDH or relative expression to
levels detected in controls.
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Western blotting
Cells were lysed in RIPA buffer with COMPLETE protease inhibitors
(Boerhinger, Ingelheim am Rhein, Germany). Protein concentration
was determined using the Pierce BCA kit (Rockford, IL) and 15 mg of
protein was loaded per well. Chemiluminescence data from western
blots were collected and quantitated using a Kodak IS2000NM
Imager (Rochester, NY).
Statistics
Two-tailed Student’s t-test was used to calculate statistical signifi-
cance for differences between groups. Pp0.05 was considered
statistically significant.
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